Cassava Sciences Inc

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cassava Sciences advances Phase III trial with strong financial footing

Cassava Sciences is progressing well with Phase III trial milestones and financial stability, poised to announce critical trial results by year-end.
While facing challenges in data accuracy and increased expenses, the company's proactive approach and strategic planning present significant growth opportunities.
By focusing on innovation and market transformation, Cassava Sciences is positioned to redefine Alzheimer's disease diagnosis and treatment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

Cassava Biosciences (NASDAQ: SAVA ) stock is tumbling 30% in pre-market trading after Reuters reported today that the Justice Department has launched a criminal probe of the company. The news service cited two unnamed individuals as its sources for the article.

Cassava (SAVA) Stock Falls 30% on Report of Criminal Probe

A Texas-based pharmaceutical company is facing a criminal probe into allegations that it manipulated data in its studies on its Alzheimer's drug simuflam on Wednesday.

US opens criminal probe into pharma company over potential Alzheimer's drug fraud: report

Shares of Cassava Sciences Inc. SAVA, +0.14% plunged 24.2% in premarket trading on Wednesday after Reuters reported that the Justice Department is investigating whether the company manipulated clinical data for a still-investigational Alzheimer's disease drug, citing people familiar with the matter. Cassava put out a news release in December that said a scientific journal did not find evidence of manipulated data in a 2005 paper authored by the company's scientists after short sellers alleged data manipulation in some previously published research.

Cassava's stock dives 24% after report citing alleged criminal probe of data from Alzheimer's drug trial

The U.S. Justice Department has opened a criminal investigation into Cassava Sciences Inc involving whether the biotech company manipulated research results for its experimental Alzheimer's drug, two people familiar with the inquiry said.

Exclusive-Cassava Sciences faces U.S. criminal probe tied to Alzheimer's drug, sources say

Cleveland-Cliffs

Express

Greenidge Generation Holdings

Robinhood

Nokia

SNDL Inc.

'Meme mania' has long since passed, but there may be an opportunity with these seven meme stocks trading at a discount right now. The post 7 Meme Stocks Trading at a Massive Discount Right Now appeared first on InvestorPlace.

7 Meme Stocks Trading at a Massive Discount Right Now

Wilmington, Delaware--(Newsfile Corp. - July 7, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Cassava Sciences, Inc. (NASDAQ: SAVA) on behalf of stockholders.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-cassava-sciences-inc.To contact Seth D. Rigrodsky or Gina M. Serra cost free, call or text (302) 295-5310 or email info@rl-legal.com.Rigrodsky Law, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on...

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Cassava Sciences, Inc.

One probably should not invest in Cassava Sciences until all investigations are completed. Alternative mechanisms of action exist that better explain Cassava Sciences' trial results than the one offered by the company.

Cassava Sciences And Alzheimer's Disease: A Precipitious Path

BigBear.ai Holdings

Fisker Inc

Meta Materials

Vertex Energy

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.

5 Short Squeeze Candidates To Watch This Week: 2 Former SPACs Join Leaderboard With BigBear.AI Topping List

- $209.7 Million Cash and Cash Equivalents at March 31, 2022 –

Cassava Sciences Reports First Quarter Financial Results for 2022 and Updates on Phase 3 Clinical Program

Cassava Sciences is facing criticism around its lead drug candidate. If that drug doesn't work, SAVA stock has a lot farther left to fall.

Cassava Sciences May Be Heading Below $10 Per Share

Serious allegations have been made against Cassava by multiple sources, making SAVA stock far too risky for investors at this point. The post Stay Far Away From Cassava Sciences Amid Data Integrity Criticisms appeared first on InvestorPlace.

Stay Far Away From Cassava Sciences Amid Data Integrity Criticisms

Cassava could run back to $40 again. Should the company get a positive nod for its Alzheimer's treatment, it could see $140 again.

Take Full Advantage of Weakness in Cassava Sciences Stock

FDA approval for Simufilam and successful trials of a new blood test to detect Alzheimer's disease could help propel SAVA stock back up. The post Cassava Sciences Is a Worthwhile Bet to Consider appeared first on InvestorPlace.

Cassava Sciences Is a Worthwhile Bet to Consider

- Q&A Session at Conference on Wednesday, April 27 th at 1:30PM Eastern -

Cassava Sciences Invited to Participate in B. Riley Securities' Neuroscience Conference

NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) on behalf of Cassava stockholders. Our investigation concerns whether Cassava has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On April 18, 2022, The New York Times published an article entit

CASSAVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Cassava Sciences, Inc. on Behalf of Cassava Stockholders and Encourages Investors to Contact the Firm

As perceptions rise that its flagship drug candidate won't make it to market, steer clear of SAVA stock. The post The Crowd Has Wisely Soured on Cassava Sciences Stock appeared first on InvestorPlace.

The Crowd Has Wisely Soured on Cassava Sciences Stock

The shares of Cassava Sciences Inc (NASDAQ:SAVA) are taking a drubbing this morning, last seen down 23.6% at $19.35, and set for their lowest open since January 2021.

Fresh Crop of Concerns Surrounding Alzheimer's Drug Sinks SAVA

Cassava Sciences Inc (NASDAQ: SAVA) shares are shedding over 20% after The New York Times detailed new allegations related to the studies of the company's experimental Alzheimer's therapy, simufilam. Among the latest concerns highlighted in the NYT article include a report.

New York Times Report Fresh Allegations On Cassava's Simufilam Alzheimer's Trials, Shares Fall

SAVA stock is tumbling after The New York Times reported that multiple experts are skeptical about Cassava's data and its main theory. The post Why Is Cassava Sciences (SAVA) Stock Down Today?

Why Is Cassava Sciences (SAVA) Stock Down Today?

The company has no debt and is cash rich. If it receives FDA approval for its Simufilam drug, the SAVA stock price will catapult.

Cassava Sciences Is Worth Considering After Hitting Its Latest Trough

Cassava Sciences is trading near its 52 week lows.

3 Key Points To Remember About Cassava Sciences

– All Stakeholder Are Welcome to Listen by Webcast –

Webcast Details for Cassava Sciences' Upcoming Fireside Chat

It helps to have plenty of cold, hard cash.

Here's Why Cassava Sciences Stock Could Make a Comeback

SAVA stock is volatile but worthwhile after opinion shifts in its favor. Remember, it has a blockbuster Alzheimer's drug nearing launch.

Risk-on Biotech Investors Should Buy Cassava Sciences

– CEO Remi Barbier to Discuss Q1 2022 Clinical and Corporate Updates –

News for Cassava Sciences Inc Stock (SAVA)